

**CLINICAL REVIEW**

Application Type NDA  
Application Number 204063  
Priority or Standard Standard

Submit Date 2-27-2012  
Received Date 2-27-2012  
PDUFA Goal Date 3-27-2013  
Division / Office DNP/OND 1/ ODE 1

Reviewer Name Heather Fitter, M.D.  
Review Completion Date 11-08-2012

Established Name BG00012 (BG-12)  
(Proposed) Trade Name Tecfidera  
Therapeutic Class Dimethyl Fumarate  
Applicant Biogen Idec

Formulation Oral  
Dosing Regimen 240 mg bid  
Indication



Intended Population Relapsing forms of Multiple Sclerosis

Template Version: March 6, 2009

Reference ID: 3214416

---

## Table of Contents

<b>1</b>	<b>RECOMMENDATIONS/RISK BENEFIT ASSESSMENT .....</b>	<b>7</b>
1.1	Recommendation on Regulatory Action .....	7
1.2	Risk Benefit Assessment.....	8
1.3	Recommendations for Postmarket Risk Evaluation and Mitigation Strategies ...	9
1.4	Recommendations for Postmarket Requirements and Commitments .....	9
<b>2</b>	<b>INTRODUCTION AND REGULATORY BACKGROUND .....</b>	<b>9</b>
2.1	Product Information .....	9
2.2	Tables of Currently Available Treatments for Proposed Indications .....	10
2.3	Availability of Proposed Active Ingredient in the United States .....	13
2.4	Important Safety Issues with Consideration to Related Drugs.....	13
2.5	Summary of Presubmission Regulatory Activity Related to Submission .....	14
<b>3</b>	<b>ETHICS AND GOOD CLINICAL PRACTICES.....</b>	<b>16</b>
3.1	Submission Quality and Integrity .....	16
3.2	Compliance with Good Clinical Practices .....	17
3.3	Financial Disclosures.....	18
<b>4</b>	<b>SIGNIFICANT EFFICACY/SAFETY ISSUES RELATED TO OTHER REVIEW DISCIPLINES .....</b>	<b>20</b>
4.1	Chemistry Manufacturing and Controls .....	20
4.2	Preclinical Pharmacology/Toxicology .....	21
4.3	Clinical Pharmacology .....	23
4.3.1	Mechanism of Action.....	23
4.3.2	Pharmacodynamics.....	23
4.3.3	Pharmacokinetics.....	24
<b>5</b>	<b>SOURCES OF CLINICAL DATA.....</b>	<b>25</b>
5.1	Tables of Studies/Clinical Trials.....	25
5.2	Review Strategy.....	26
5.3	Discussion of Individual Clinical Trials .....	26
5.3.1	Protocol C-1900 .....	26
5.3.1.1	Efficacy Results Trial C-1900.....	27
5.3.1.1.1	Trial Population .....	27
5.3.1.1.2	Efficacy Analysis .....	28
5.3.2	Protocol 109MS301.....	30
5.3.2.1	Efficacy Results Trial 301.....	48
5.3.2.1.1	Trial Population .....	48
5.3.2.1.2	Efficacy Analysis .....	51
5.3.3	Protocol 109MS302.....	64
5.3.3.1	Efficacy Results Trial 302.....	70
5.3.3.1.1	Trial Population .....	70
5.3.3.1.2	Efficacy Analysis .....	74

---

5.3.4 Protocol 109MS303.....	87
5.3.4.1. Efficacy Results Trial 303.....	88
5.3.4.1.1 Trial Population .....	88
5.3.4.1.2 Efficacy Analysis .....	88
<b>6 REVIEW OF EFFICACY.....</b>	<b>90</b>
6.1 Indication .....	90
6.1.1 Methods .....	90
6.1.2 Demographics .....	90
6.1.3 Subject Disposition.....	92
6.1.4 Analysis of Primary Endpoints.....	94
6.1.5 Analysis of Secondary Endpoints.....	95
6.1.5.1 Number of New or Newly Enlarging T2 Hyperintense Lesions .....	95
6.1.5.2 Number of Gd-enhancing lesions at 2 years .....	96
6.1.5.3 New T1 hypointense lesions .....	97
6.1.5.4 Annualized relapse rate/proportion relapsing.....	98
6.1.5.5 Disability progression .....	99
6.1.6 Other Endpoints .....	101
6.1.7 Subpopulations .....	102
6.1.8 Analysis of Clinical Information Relevant to Dosing Recommendations ...	105
6.1.9 Discussion of Persistence of Efficacy and/or Tolerance Effects.....	106
6.1.10 Discussion of the Presence of Withdrawal Effects .....	107
6.1.11 Additional Efficacy Issues/Analyses .....	108
<b>7 REVIEW OF SAFETY.....</b>	<b>113</b>
<b>8 POSTMARKET EXPERIENCE.....</b>	<b>113</b>
<b>9. APPENDICES .....</b>	<b>113</b>
9.1 Labeling Recommendations .....	113
9.2 Advisory Committee Meeting.....	113

---

## Table of Tables

Table 1: Table of currently available treatments for proposed indications.....	11
Table 2: Financial disclosure trial 301, earnings over \$100,000 and enrollment $\geq 5$ .....	19
Table 3: Financial disclosure trial 302, earnings over \$100,000 and enrollment $\geq 5$ subjects, with one exception. ....	20
Table 4: List of BG-12 trials that contributed to efficacy analysis .....	26
Table 5: Study C-1900 summary of key efficacy results (efficacy evaluable population) .....	29
Table 6: Laboratory criteria requiring withholding or permanent discontinuation of blinded study treatment.....	35
Table 7: Blinded study treatment dosing regimen .....	37
Table 8: Trial 301 study activities, visit 1-12, chart 1/3.....	38
Table 9: Trial 301 study activities: visits 13-25, chart 2/3 .....	39
Table 10: Trial 301 study activities with premature study withdrawal visit and unscheduled relapse visit, chart 3/3.....	39
Table 11: Disposition of subjects in trial 301 .....	49
Table 12: Summary of number of subjects and reasons for exclusion from the per- protocol population (trial 301) .....	50
Table 13: Baseline MRI evaluation- MRI cohort Trial 301 .....	51
Table 14: Summary of the proportion of subjects relapsed (INEC confirmed relapses) at 2 years -ITT .....	52
Table 15: Summary of proportion of subjects relapsed (INEC confirmed) at 2 years - sensitivity analysis reassigning status of patients that reported an unknown relapse status-ITT population .....	53
Table 16: Results of sensitivity analyses of the primary endpoint (trial 301) .....	54
Table 17: Number of new or newly enlarging T2 lesions at 2 years compared to baseline-MRI cohort (trial 301).....	55
Table 18: Number of Gd enhancing lesions at 2 years-MRI cohort (trial 301).....	55
Table 19: Summary of ARR (INEC confirmed) at 2 years- ITT population .....	56
Table 20: Summary of time to confirmed progression of disability as measured by an increase in EDSS (12 week confirmation)-ITT (trial 301).....	57
Table 21: Change of MSFC z score from baseline to 2 years- ITT (trial 301) .....	59
Table 22: MSFC: Change of actual scores from baseline to 2 years- ITT population (trial 301).....	60
Table 23: Subgroup analyses (trial 301).....	63
Table 24: Key demographic and baseline characteristics- MRI cohort and non-MRI cohort (trial 302).....	74
Table 25: Summary of ARR (INEC confirmed) at 2 years-ITT (trial 302).....	76
Table 26: MRI: Number of new or newly enlarging T2 lesions at 2 years compared to baseline- MRI cohort (trial 302).....	77
Table 27: Number of new T1 hypointense lesions at 2 years compared to baseline- MRI cohort (trial 302).....	78
Table 28: Summary of time to confirmed disability progression at 2 years- per protocol population (trial 302) .....	81

---

Table 29: MSFC: Change of raw scores from baseline to 2 years- ITT (trial 302).....	82
Table 30: ARR with 95% CI for subjects randomized to placebo then active study treatment (trial 303).....	90
Table 31: Demography in terms of distribution of regions between trials and treatment groups.....	91
Table 32: Trial subject disposition .....	92
Table 33: Efficacy results of ARR and proportion relapsing- ITT (trials 301 and 302)...	94
Table 34: Number of new and newly enlarging T2 hyperintense lesions at 2 years compared to baseline (trial 301 and 302).....	96
Table 35: Number of Gd enhancing lesions at 2 years- MRI cohort (trials 301, 302) ....	97
Table 36: Number of new T1 hypointense lesions over 2 years- MRI cohort (trial 301 and 302).....	98
Table 37: Disability progression in trial 301, 302 and pooled analysis .....	101
Table 38: Summary of ARR (INEC confirmed) at 2 years by EDSS score (trials 301 and 302 pooled).....	103
Table 39: Summary of proportion of subjects relapsed (INEC confirmed) at 2 years by region- ITT (trial 301) .....	104
Table 40: Summary of ARR (INEC confirmed) at 2 years by region- ITT (trial 302)...	105
Table 41: Estimated proportion of relapsing patients based on the presence of the adverse event of flushing (trial 301).....	108
Table 42: Estimated ARR based on the presence of the adverse event of flushing (trial 302).....	108
Table 43: Summary of proportion of subjects relapsed (INEC confirmed) at 2 years by dose reduction/interruption status (trial 301).....	110
Table 44: Summary of ARR (INCEC confirmed) at 2 years by dose reduction/interruption status (trial 302).....	110
Table 45: Summary of the proportion of subjects relapsed (INEC confirmed) at 2 years by the presence of minimum post baseline lymphocyte count <LLN (trial 301) .....	112
Table 46: Summary of ARR (INEC confirmed) at 2 years by the presence of minimum post baseline lymphocyte count <LLN (trial 302) .....	112

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.